Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

48.40 +0.81 (+1.70%)

Streaming Delayed Price Updated: 10:51 AM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

34 35 Next >

Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks ↗

October 31, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...

Via Benzinga

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More ↗

October 28, 2023

The U.S.

Via Benzinga

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars? ↗

October 28, 2023

The three companies are spending big on IBD therapies.

Via The Motley Fool

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

October 27, 2023

From Genentech

Via Business Wire

It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy ↗

October 24, 2023

The market's dour reaction to Roivant Sciences' latest deal doesn't add up.

Via The Motley Fool

Why Is Roivant Sciences (ROIV) Stock Up Today? ↗

October 23, 2023

ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates.

Via InvestorPlace

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

October 23, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END

Via FinancialNewsMedia

Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space ↗

October 23, 2023

Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.

Via Investor's Business Daily

Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal ↗

October 23, 2023

Roche Holding AG (OTC: RHHBY) inked a deal to acquire

Via Benzinga

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

October 23, 2023

From Roivant Sciences

Via GlobeNewswire

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? ↗

October 21, 2023

The venerable pharmaceutical companies' shares have slumped this year.

Via The Motley Fool

Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance ↗

October 19, 2023

The company's third-quarter sales also declined and came in light.

Via Investor's Business Daily

Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products ↗

October 19, 2023

Roche Holdings AG's (OTC: RHHBY) nine months

Via Benzinga

Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer

October 18, 2023

From Genentech

Via Business Wire

What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? ↗

October 17, 2023

Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:

Via Benzinga

FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication ↗

October 17, 2023

The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing...

Via Benzinga

Why Is Alzheimer's Player Prothena Stock Trading Higher Today? ↗

October 16, 2023

Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale.

Via Benzinga

AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points ↗

October 14, 2023

Broadcom and Arista lead five stocks sporting a flat base.

Via Investor's Business Daily

Topics Artificial Intelligence

Late-Breaking Data for Genentech’s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis

October 13, 2023

From Genentech

Via Business Wire

New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided

October 12, 2023

From Genentech

Via Business Wire

TPST Stock: 7 Things to Know About Tempest Therapeutics ↗

October 11, 2023

Are you curious about the recent surge from Tempest Therapeutics? Here's a closer look at this company and at TPST stock.

Via InvestorPlace

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗

October 11, 2023

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...

Via Benzinga

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

October 11, 2023

From Genentech

Via Business Wire

First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity

October 11, 2023

From Genentech

Via Business Wire

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

October 10, 2023

From Genentech

Via Business Wire

Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update ↗

October 04, 2023

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c

Via Benzinga

Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment

October 04, 2023

From Genentech

Via Business Wire

Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich ↗

October 03, 2023

Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich.

Via InvestorPlace

2 Cathie Wood Stocks That Could Deliver Exponential Returns ↗

October 02, 2023

These two cutting-edge healthcare companies could be significantly undervalued right now.

Via The Motley Fool

Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD

October 02, 2023

From Genentech

Via Business Wire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.